Related Experiment Video
Updated: Sep 10, 2025

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
Transforming Atopic Dermatitis Management: Probiotics as a Game-Changer in Immune Modulation-A Double-Blind,
Caterina Mariarosaria Giorgio1, Gaetano Licata2, Raffaele Sorbo3
1From the, Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
Abstract:
Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by immune dysregulation and microbiota imbalances. It affects millions worldwide, leading to significant morbidity and reduced quality of life. The disease is marked by intense pruritus, xerosis, and eczematous lesions, often accompanied by psychological distress and sleep disturbances. Recent research has established a strong association between gut dysbiosis and AD pathogenesis, suggesting that interventions targeting the gut microbiota may offer therapeutic benefits.Objective: This study aimed to evaluate the effects of a high-dose multistrain probiotic formulation, DSF Formulation®, on disease severity and immune modulation in adult patients with moderate-to-severe AD.Methods: A double-blind, randomized, placebo-controlled trial was conducted, enrolling 80 adult patients diagnosed with AD. Participants were randomly assigned to receive either DSF Formulation® or a placebo for 60 days. Clinical outcomes were assessed using Scoring Atopic Dermatitis (SCORAD), Eczema Area and Severity Index (EASI), and Dermatology Life Quality Index (DLQI) scoring systems, while immunological parameters were evaluated by measuring cytokine levels (IL-4, IL-10, and TGF-β) via enzyme-linked immunosorbent assay.Results: Probiotic supplementation resulted in a significant reduction in SCORAD, EASI, and DLQI scores compared to the placebo group (P < 0.05). Additionally, a substantial decrease in IL-4 levels was observed in the probiotic-treated group, alongside a significant increase in IL-10 and TGF-β levels (P < 0.05), indicating a shift towards an anti-inflammatory immune response.Conclusion: These findings suggest that DSF Formulation® may serve as an effective adjunctive therapy for AD by modulating the gut microbiota and promoting an anti-inflammatory immune response. Furthermore, studies are warranted to confirm these results, assess long-term clinical implications, and determine the optimal probiotic formulations for therapeutic use.
More Related Videos
Related Concept Videos
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

